prikaz prve stranice dokumenta Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease
  Download
PDF 5 MB
Scientific paper - Original scientific paper
Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease
Neuropharmacology, 135 (2018); 48-62. https://doi.org/10.1016/j.neuropharm.2018.02.027
Knezović, Ana; Osmanović Barilar, Jelena; Babić, Ana; Bagarić, Robert; Farkaš, Vladimir; Riederer, Peter; Šalković-Petrišić, Melita

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Knezović, A., Osmanović Barilar, J., Babić, A., Bagarić, R., Farkaš, V., Riederer, P. & Šalković Petrišić, M. (2018). Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease. Neuropharmacology, 135., 48-62. doi: 10.1016/j.neuropharm.2018.02.027

Knezović, Ana, et al. "Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease." Neuropharmacology, vol. 135, 2018, pp. 48-62. https://doi.org/10.1016/j.neuropharm.2018.02.027

Knezović, Ana, Jelena Osmanović Barilar, Ana Babić, Robert Bagarić, Vladimir Farkaš, Peter Riederer and Melita Šalković Petrišić. "Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease." Neuropharmacology 135 (2018): 48-62. https://doi.org/10.1016/j.neuropharm.2018.02.027

Knezović, A., et al. (2018) 'Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease', Neuropharmacology, 135, pp. 48-62. doi: 10.1016/j.neuropharm.2018.02.027

Knezović A, Osmanović Barilar J, Babić A, Bagarić R, Farkaš V, Riederer P, and sur.. Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease. Neuropharmacology [Internet]. 2018 June [cited 2024 November 22];135:48-62. doi: 10.1016/j.neuropharm.2018.02.027

A. Knezović, et al., "Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease", Neuropharmacology, vol. 135, pp. 48-62, June 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:353238. [Accessed: 22 November 2024]

Metadata
Title (english)Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease
AuthorAna Knezović
AuthorJelena Osmanović Barilar
AuthorAna Babić
AuthorRobert Bagarić
AuthorVladimir Farkaš
AuthorPeter Riederer
AuthorMelita Šalković-Petrišić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Insulin resistance and metabolic dysfunction in the brain are considered to be the pathophysiological core of sporadic Alzheimer's disease (sAD). In line with that fact, nutrients that could have therapeutic effects at this level have been investigated as possible targets in AD therapy. Galactose, an epimer of glucose, may serve as an alternative source of energy, and given orally may stimulate secretion of the incretin hormone glucagon-like peptide-1 (GLP-1). Our preliminary research indicated that oral galactose might prevent development of memory impairment in a rat model of sAD generated by intracerebroventricular administration of streptozotocin (STZ-icv). Here, we explored whether chronic oral galactose treatment could have beneficial effects on cognitive deficits already manifested at the time of initiation of galactose treatment in adult STZ-icv rats (treatment initiated 1 month after STZ-icv injection). The results clearly show that a 2-month exposure to oral galactose (200 mg/kg/day administered in a drink ad libitum) normalises impaired learning and memory functions. Memory improvement was accompanied by an improvement in brain glucose hypometabolism measured by 18fluorodeoxyglucose-positron emission tomography neuroimaging and by increments in active GLP-1 plasma levels as well as by an increased expression of GLP-1 receptors in the hippocampus and hypothalamus. Our findings provide strong evidence of beneficial effects of oral galactose treatment in the STZ-icv rat model of sAD and present possible underlying mechanisms including both direct effects of galactose within the brain and indirect GLP-1-induced neuroprotective effects that might open a new, dietary-based strategy in sAD treatment.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleNeuropharmacology
Numberingvol. 135, pp. 48-62
p-ISSN0028-3908
DOIhttps://doi.org/10.1016/j.neuropharm.2018.02.027
URN:NBNurn:nbn:hr:105:353238
Publication2018-06
Document URLhttps://doi.org/10.1016/j.neuropharm.2018.02.027
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 10:14:44